Exploiting microbial exposure to study the immune response to uropathogenic E. coli
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
批准号:
10237569
负责人:
Thomas S Griffith
金额:
$23.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-06-01 至 2023-05-31
关键词:
AdultAffectBacteremiaBacteriaBiologyBiomedical ResearchBirthBladderBladder DiseasesBlood CirculationCathetersCellsCessation of lifeClinicalClinical ResearchCommunicable DiseasesComplementDataDevelopmentEscherichia coliEscherichia coli InfectionsExhibitsExperimental ModelsExposure toFoundationsFunctional disorderGenerationsGlobal ChangeGoalsHospitalsHousingHumanHuman BiologyImmuneImmune responseImmune systemInfectionInfection preventionInflammatory ResponseKidneyKnowledgeLaboratory miceLungModelingMorbidity - disease rateMucous MembraneMusOrganPathologyPhysiologicalPredispositionPyelonephritisRecurrenceReproducibilityResearchSepsisSiteSkinSystemic infectionTestingTrainingTranslatingUrinary tract infectionUropathogenic E. coliWomanWorkagedclinically relevantcommensal microbesefficacious treatmentemerging pathogenexperienceexperimental studyfitnessgerm free conditionimmune functionin vivointravesicalmicrobialmortalitymouse modelneonatal humanneonatenosocomial UTInovelpathogenic microbepolymicrobial sepsispre-clinicalpreventrecurrent infectionresponsetooltreatment responseurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The bladder is a frequent site of infection, as ~50% of women aged 18-50 years will have at least one urinary
tract infection (UTI) and ~40% of hospital-acquired nosocomial infections are UTIs after urinary catheter
introduction. Most UTIs are caused by uropathogeneic E. coli (UPEC), starting with bladder colonization and
then ascension to the kidneys. In severe cases of pyelonephritis, the bacteria can enter the bloodstream –
causing bacteremia, sepsis (urosepsis), and death. Importantly, the immune system is involved in the
development of these pathologies and response to treatment. The dominant in vivo mammalian model used in
biomedical research is the mouse. However, environmental microbial exposure is an important difference
between basic human and laboratory mouse biology that must be considered when using mouse models to
evaluate the fitness of the immune system. Humans are naturally exposed to commensal and pathogenic
microbes from birth, and the immune system of adult humans consequently becomes trained by each
encounter. In contrast, laboratory mice are often housed under specific pathogen-free (SPF) conditions. While
SPF housing has been key in increasing experimental reproducibility, it has simultaneously further distanced
the mouse model from humans, largely because SPF mice live their lives with limited microbial exposure.
This proposal leverages a novel mouse model that mimics a critical aspect of human biology – exposure to
multiple ongoing and resolved infections trains the immune system for robust responses to new pathogens.
Our central hypothesis holds that the matured immune system in microbially-experienced dirty mice will
respond with a more robust immune response in the bladder after local UPEC infection and accelerated UTI
clearance, but an exaggerated inflammatory response and increased mortality during systemic urosepsis.
The overall goal of this project is to study how changing the “starting point” of the immune system (i.e., naïve,
neonate-like immune system of SPF mice vs. mature, adult-like immune system in ‘dirty’ mice after
physiological microbial exposure) affects the immune response local and systemic UPEC infections. Our
rationale for the studies with ‘dirty’ mice is that we will amass a valuable new foundation of information
regarding UTI and urosepsis-induced immune responses and pathophysiology. Ultimately, the data obtained
from the proposed studies will be of great relevance to the understanding UTIs. It is important to emphasize
our ‘dirty’ mouse model is meant to be a novel complement to, rather than a replacement of, the SPF mice
typically used in research, and serve as a valuable tool to discover new efficacious therapies that may be
sensitive to unique environmental perturbations resulting from physiological microbial exposure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLRD Research Career Scientist Award Application
-
批准号:10582394
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Thomas S Griffith
-
依托单位:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
-
批准号:10257687
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
CD4 T cell dysfunction and reprogramming during sepsis
-
批准号:10633073
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
-
批准号:10413143
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
-
批准号:10512750
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
CD4 T cell dysfunction and reprogramming during sepsis
-
批准号:10400169
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Alterations in CD4 T cells during sepsis
-
批准号:9101373
-
项目类别:
-
资助金额:$31.59万
-
财政年份:2016
-
负责人:Thomas S Griffith
-
依托单位:
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis
-
批准号:10084212
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Suppression of T cell immunity during sepsis
-
批准号:8601255
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Suppression of T cell immunity during sepsis
-
批准号:8237299
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Using microbially-experienced mice to study the innate immune response in sepsis
-
批准号:10655287
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Using microbially-experienced mice to study the innate immune response in sepsis
-
批准号:10367761
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Apoptotic cells induce tolerance through TRAIL-expressing CD8+ regulatory T cells
-
批准号:7892840
-
项目类别:
-
资助金额:$37.19万
-
财政年份:2009
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL: A MECHANISM FOR BCG-INDUCED ANTI-TUMOR ACTIVITY IN BLADDER CANCER
-
批准号:7604865
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2007
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:7227055
-
项目类别:
-
资助金额:$25.8万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:8255342
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:7851372
-
项目类别:
-
资助金额:$26.88万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:6901940
-
项目类别:
-
资助金额:$27.21万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:6816995
-
项目类别:
-
资助金额:$27.21万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:8484212
-
项目类别:
-
资助金额:$24.29万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
海外基金